EV/EBITDA Multiple: Rhythm Pharmaceuticals Inc (RYTM)
Rhythm Pharmaceuticals (RYTM) relies on organic growth without mergers, which is reflected on the GURU.Markets platform in the EV/EBITDA valuation multiple history, where the current value stands at 0.00. A monopoly in the treatment of rare obesity guarantees a steady cash flow. However, geopolitical tensions and raw material logistics disruptions create certain risks for the company's global research.
rhythmtx.com (RYTM) - metric breakdowns and financial figures
- market price and analyst price targets:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- debt and liquidity data:
Total Debt to Capital Rhythm Pharmaceuticals|RYTM - Long-Term Debt to Equity|Short-Term Debt to Equity Rhythm Pharmaceuticals, Inc.|RYTM - Company Cumulative Debt|Debt to Book Capitalization Ratio Rhythm Corp|RYTM - Company Long-Term Debt|Company Short-Term Debts Rhythm Pharmaceuticals|Quick Liquidity rhythmtx.com
- net income and valuation multiples indicators:
RYTM - Net Financial Result|Expected Profit Rhythm Pharmaceuticals|RYTM - Price to Earnings Ratio|Future Price to Earnings Rhythm Pharmaceuticals|RYTM - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Rhythm Corp|RYTM - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months Rhythm Pharmaceuticals|RYTM - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months rhythmtx.com|RYTM - Net earnings per one share growth for the current year|Earnings growth forecast for next year Rhythm Pharmaceuticals
Initial company analysis:RYTM (Rhythm Pharmaceuticals Inc)
The absolute pricing power of Rhythm Pharmaceuticals (RYTM), driven by the uniqueness of Imcivree, makes the company's EV/EBITDA ratio, adjusted for debt load, a key tool for valuing the business relative to its operational efficiency. By analyzing the dynamics of this multiple, an investor determines whether the current market capitalization and net debt are justified by the ability to generate earnings before interest, taxes, depreciation, and amortization.
Who Rhythm Pharmaceuticals competes with
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Ascendis Pharma Inc. ASND|MDGL - Enterprise Value to EBITDA Ratio|Corcept Therapeutics - EV/EBITDA Multiple|Company Value to EBITDA akerotx.com|MTSR (Metsera) - Enterprise Value to EBITDA Ratio|MLTX: Enterprise Value to Operating Income Before Depreciation Ratio|CRNX (Crinetics Pharma) - EV/EBITDA Multiple|EV/EBITDA Multiple NewAmsterdam Pharma Corp|EV/EBITDA Multiple SLNO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization FOLD (amicusrx.com)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization 89bio ETNB|Agios (AGIO) - Company Value to EBITDA|GPCR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MDXG: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|RZLT: EV/EBITDA Multiple|LXRX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MBX Biosciences|Altimmune Inc (ALT) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aardvark Therapeutics Corp (AARD)|Enterprise Value to EBITDA Ratio Sagimet Biosciences Inc SGMT|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization BioAge Labs, Inc. BIOA|Business Value to Operating Income Before Depreciation BMEA|Quince - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation GUTS (Fractyl Health Inc.)|VTVT (vtvtherapeutics.com) - Enterprise Value to EBITDA Ratio|Company Value to EBITDA Agape ATP (ATPC)|Enterprise Value to EBITDA Ratio PLUR|SYBX (Synlogic Corp) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple LPCN|MTNB (matinasbiopharma.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Spruce Biosciences SPRB|GLTO - Enterprise Value to EBITDA Ratio|CTCX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation LUMO (lumos-pharma.com)|Organovo (ONVO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio RDUS (Radius Recycling Inc.)
